To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:193 Issue:1 Number:1 ISSN#:2564-2537
Author Verified
RCT
ACE Report #14310
Ace Report Cover Trauma

Subcutaneous Teriparatide for Pelvic Fracture Healing: A Phase 2 Randomized Controlled Trial


How to Cite

OrthoEvidence. Subcutaneous Teriparatide for Pelvic Fracture Healing: A Phase 2 Randomized Controlled Trial. ACE Report. 2022;193(1):1. Available from: https://myorthoevidence.com/AceReport/Report/14310

Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Teriparatide and pelvic fracture healing: a phase 2 randomized controlled trial.

Osteoporos Int. 2022 Jan;33(1): 239-250.

Contributing Authors:
JW Nieves F Cosman D McMahon M Redko I Hentschel R Bartolotta M Loftus JJ Kazam J Rotman J Lane

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

Thirty-five patients over the age of 50 with an acute pelvic fracture were randomized to receive 3 months of subcutaneous teriparatide injections (n=18) or placebo injections (n=17). Outcomes of interest included pain scores on a Numeric Rating Scale (NRS), physical performance scores (Continuous Summary Physical Performance Score [CSPPS]; timed up and go), and bone healing. Results revealed no si...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE
For Reprints and Permissions, click here

Please Login or Join to leave comments.